Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedApr 02, 2026
DataAggregated Company Financials
Companies56
  • 7D-0.02%
  • 3M-13.2%
  • 1Y29.8%
  • YTDn/a

Over the last 7 days, the Pharma industry has dropped 2.0%, driven by pullbacks in Trulieve Cannabis and Curaleaf Holdings of 8.5% and 5.1%, respectively. In contrast, Knight Therapeutics has gained 8.8%. Over the past 12 months, the industry was up 26%. Earnings are forecast to grow by 49% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Apr 2026CA$13.5bCA$11.4b-CA$1,682,598,701.2312.6x-8x1.2x
Sat, 28 Feb 2026CA$14.6bCA$11.2b-CA$1,765,189,451.0013.2x-8.2x1.3x
Mon, 26 Jan 2026CA$16.4bCA$11.2b-CA$1,938,988,736.7116.3x-8.5x1.5x
Wed, 24 Dec 2025CA$16.2bCA$11.2b-CA$1,937,220,386.8415.7x-8.4x1.4x
Fri, 21 Nov 2025CA$12.3bCA$11.4b-CA$1,931,738,091.8914.2x-6.3x1.1x
Sun, 19 Oct 2025CA$16.7bCA$11.3b-CA$2,041,111,924.7235.7x-8.2x1.5x
Tue, 16 Sep 2025CA$15.3bCA$11.2b-CA$2,026,925,437.8039.7x-7.5x1.4x
Thu, 14 Aug 2025CA$16.3bCA$11.7b-CA$2,532,480,838.5022.7x-6.4x1.4x
Sat, 12 Jul 2025CA$10.8bCA$11.7b-CA$2,538,599,628.3419.6x-4.3x0.9x
Mon, 09 Jun 2025CA$9.8bCA$11.7b-CA$2,523,132,318.4618x-3.9x0.8x
Wed, 07 May 2025CA$10.8bCA$11.9b-CA$2,464,224,800.0120.1x-4.4x0.9x
Fri, 04 Apr 2025CA$10.1bCA$12.2b-CA$2,602,022,548.6318.6x-3.9x0.8x
Sun, 02 Mar 2025CA$11.6bCA$12.3b-CA$2,414,712,558.1722.4x-4.8x0.9x
Tue, 28 Jan 2025CA$12.3bCA$12.1b-CA$2,412,356,577.5330.9x-5.1x1x
Thu, 26 Dec 2024CA$12.7bCA$12.1b-CA$2,410,973,342.5624.3x-5.3x1x
Sat, 23 Nov 2024CA$14.1bCA$11.8b-CA$2,558,902,656.5118.4x-5.5x1.2x
Mon, 21 Oct 2024CA$19.2bCA$11.8b-CA$2,708,717,422.1217.4x-7.1x1.6x
Wed, 18 Sep 2024CA$18.5bCA$11.6b-CA$2,699,222,813.8120.9x-6.8x1.6x
Fri, 16 Aug 2024CA$19.4bCA$11.7b-CA$2,766,813,006.6923.6x-7x1.7x
Sun, 14 Jul 2024CA$20.0bCA$11.7b-CA$3,177,476,587.8519.1x-6.3x1.7x
Tue, 11 Jun 2024CA$20.9bCA$11.8b-CA$2,775,247,746.6612.9x-7.5x1.8x
Thu, 09 May 2024CA$23.4bCA$11.9b-CA$3,453,064,894.8910.8x-6.8x2x
Sat, 06 Apr 2024CA$24.6bCA$11.9b-CA$3,481,079,488.498.7x-7.1x2.1x
Mon, 04 Mar 2024CA$21.7bCA$12.0b-CA$4,217,629,521.489.4x-5.1x1.8x
Wed, 31 Jan 2024CA$22.7bCA$12.3b-CA$6,716,542,477.008.8x-3.4x1.8x
Fri, 29 Dec 2023CA$17.7bCA$12.2b-CA$6,707,159,626.009.1x-2.6x1.5x
Sun, 26 Nov 2023CA$17.8bCA$12.4b-CA$6,821,960,697.007x-2.6x1.4x
Tue, 24 Oct 2023CA$16.8bCA$12.4b-CA$7,337,693,416.0012x-2.3x1.4x
Thu, 21 Sep 2023CA$20.7bCA$12.9b-CA$7,880,149,538.0013.9x-2.6x1.6x
Sat, 19 Aug 2023CA$13.9bCA$13.0b-CA$8,052,240,353.0013.1x-1.7x1.1x
Mon, 17 Jul 2023CA$16.0bCA$13.2b-CA$9,718,273,603.0012.4x-1.6x1.2x
Wed, 14 Jun 2023CA$14.6bCA$13.2b-CA$10,382,733,556.0010.7x-1.4x1.1x
Fri, 12 May 2023CA$14.8bCA$13.3b-CA$10,256,145,500.009.9x-1.4x1.1x
Sun, 09 Apr 2023CA$15.5bCA$13.3b-CA$9,967,644,441.008.2x-1.6x1.2x
Price to Earnings Ratio

-1.6x


Total Market Cap: CA$15.5bTotal Earnings: -CA$9,967,644,441.00Total Revenue: CA$13.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Canadian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 1.4x is higher than the industry's current PS ratio of 1.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 5.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Canadian Pharma compare with similar industries?

CA Market1.56%
Healthcare1.61%
Pharma-0.02%
Pharma-0.02%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CRDL Cardiol TherapeuticsCA$1.9530.0%
+CA$49.9m		46.6%PB22.6x
CPH Cipher PharmaceuticalsCA$18.288.6%
+CA$36.7m		44.5%PE12.2x
GUD Knight TherapeuticsCA$7.444.6%
+CA$32.4m		20.6%PS1.6x
VRNO Verano HoldingsCA$1.554.7%
+CA$26.9m		84.5%PS0.5x
GTII Green Thumb IndustriesCA$9.103.9%
+CA$24.3m		9.8%PE13x

Latest News

VREO
CA$0.56
Vireo Growth
7D
-1.8%
1Y
-15.2%
TRUL
CA$8.10
Trulieve Cannabis
7D
-3.0%
1Y
52.8%
GRIN
CA$0.40
Grown Rogue International
7D
-7.0%
1Y
-31.0%
CURA
CA$3.11
Curaleaf Holdings
7D
-1.9%
1Y
148.8%
MVMD
CA$0.08
Mountain Valley MD Holdings
7D
60.0%
1Y
166.7%
GTII
CA$9.10
Green Thumb Industries
7D
3.9%
1Y
9.8%
VEXT
CA$0.27
Vext Science
7D
17.8%
1Y
43.2%
CRON
CA$3.48
Cronos Group
7D
-4.4%
1Y
33.8%
XLY
CA$0.13
Auxly Cannabis Group
7D
-10.3%
1Y
62.5%

Canadian Cannabis Brand Scale And EU GMP Plans Will Shape Future Earnings Potential

Catalysts About Auxly Cannabis Group Auxly Cannabis Group is a Canadian cannabis company focused on branded products across dried flower, pre rolls and vapes, supported by cultivation and processing operations at Auxly Leamington. What are the underlying business or industry changes driving this perspective?
GUD
CA$7.44
Knight Therapeutics
7D
4.6%
1Y
20.6%
CPH
CA$18.28
Cipher Pharmaceuticals
7D
8.6%
1Y
44.5%

CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution

Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.
MDP
CA$3.28
Medexus Pharmaceuticals
7D
6.1%
1Y
33.3%

MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside

Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).
VRNO
CA$1.55
Verano Holdings
7D
4.7%
1Y
84.5%
CL
CA$1.27
Cresco Labs
7D
-5.9%
1Y
33.7%

CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook

Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.
TSND
CA$0.91
TerrAscend
7D
-2.2%
1Y
40.0%
CRDL
CA$1.95
Cardiol Therapeutics
7D
30.0%
1Y
46.6%